Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Chugai's Hemlibra Launched for Congenital Hemophilia A without Inhibitors in Taiwan

TOKYO, July 4, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, has launched Hemlibra®, a drug created by Chugai for routine prophylaxis of bleeding episodes in people with hemophilia A without factor VIII inhibitors.

[Reference]
Chugai's Hemlibra Approved for Hemophilia A without inhibitors in Taiwan (Press release issued on October 30, 2019)
https://www.chugai-pharm.co.jp/english/news/detail/20191030150001_663.html

About Hemlibra

Hemlibra is a bispecific monoclonal antibody created with Chugai's proprietary antibody engineering technologies. The drug is designed to bind factor IXa and factor X. In doing so, Hemlibra provides the cofactor function of factor VIII in people with hemophilia A, who either lack or have impaired coagulation function of factor VIII.[1,2] The product was approved by the U.S. Food and Drug Administration (FDA) in November 2017, for the first time in the world, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. Hemlibra has been approved in more than 110 countries for congenital hemophilia A with and without factor VIII inhibitors.

Sources

1. Kitazawa, et al. Nature Medicine 2012; 18(10): 1570
2. Sampei, et al. PLoS ONE 2013; 8(2): e57479

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp